Case page

Intas Laboratories Pvt Ltd v Novartis AG (2004)

High Court of Madras·P.D. Dinakaran & S.R. Singharavelu JJ·Division Bench·Decided 20 December 2004·2005 (1) CTC 27

Good law Original side appeals against the Single Judge's order of 28 April 2004 disposed of: the interim injunction protecting Novartis's Exclusive Marketing Rights in the beta crystalline form of imatinib mesylate confirmed on Novartis's undertaking to supply the drug free to patients below an income limit and to meet shortfalls in insurance and reimbursement, the Single Judge's findings on the validity of the Exclusive Marketing Rights eschewed, no costs. No further appeal traced as of 20 October 2026. Interlocutory

Declining to decide the validity of the Exclusive Marketing Rights in an interim appeal, the Division Bench confirmed Novartis's imatinib injunction on an undertaking of free supply to patients.

Cite this page

Intas Laboratories Pvt Ltd v Novartis AG, Ali on Patents, www.aop.onl/intas-novartis

Judgment PDF

Summary

“These appeals are directed against the common order dated 28.4.2004” in which “the learned single Judge made absolute the order of ex parte injunction dated 20.01.2004 made in O.A.Nos. 13 to 17 of 2004 in C.S.No. 5 to 9 of 2004 in favour of the respondents/plaintiffs in each of the suits and dismissed the applications filed by the appellants/defendants to vacate the ex parte order of injunction dated 20.1.2004 in each of the suits.” (para 1) The plaintiffs sought to restrain the defendants from dealing in an “and cancer drug composed of ‘Beta-Crystalline form of Imatinib Mesylate’” “so long as the Exclusive Marketing Right granted by the Controller of Patents on 10.11.2003 under EMR” (“Exclusive Marketing Rights”) “No. 002 and notified in the Official Gazette on 13.12.2003 is subsisting” (para 2). Their case was that “by way of an interim measure, till the product patent application is taken up for consideration, provision is made in the Patents Act for granting Exclusive Marketing Rights (hereinafter referred to as ‘EMR’)” (para 3.1). “The main contention of the appellants/defendants is that the EMR obtained by the respondents/plaintiffs in each of the suits is not in accordance with the provisions of the Patents Act, 1970, as the conditions imposed under Section 24-B of the Patents Act, 1970 have not been satisfied” (para 9).

The Bench held that “it would not be proper for us to decide the said issue in appeals arising out of interim orders as the same would render the suit itself infructuous leaving nothing for the trial” (para 11), and that, the Single Judge having found the balance of convenience in the plaintiffs’ favour, “we find it difficult to interfere with the same.” (para 12.1) It held that “the public interest should not be made to suffer on account of legal battle between the trading parties, particularly in the case of supply of medicines for Chronic Myeloid Leukaemia.” (para 12.2) “Recording the undertaking of the learned Senior Counsel made on behalf of the respondents/plaintiffs, we confirm the order of interim injunction dated 28.4.2004 of the learned Single Judge” (para 14), on terms including that “the respondents/plaintiffs would supply Beta-Crystalline form of Imatinib Mesylate freely to all the patients, who are suffering from Chronic Myeloid Leukaemia and are earning less than Rs. 3,36,000 per month” (para 14(i)), and “all the original side appeals are disposed of accordingly. No costs.” (para 14(ix))

What the court decided

  1. Procedure. Validity in an interim appeal. On “the validity of the EMR” (“Exclusive Marketing Rights”) “granted in favour of the respondents/plaintiffs in each of the suits, we are of the considered opinion that it would not be proper for us to decide the said issue in appeals arising out of interim orders as the same would render the suit itself infructuous leaving nothing for the trial, as any view, opinion or finding expressed in that regard would automatically be binding on the learned Single Judge in the trial. We are, therefore, inclined to eschew any of the findings of the learned Single Judge with reference to the validity of the EMR granted in favour of the respondents/plaintiffs in each of the suit and to test the order under appeal dated 28.4.2004 only within the parameters of the balance of convenience and public interest in question.” (para 11)
  2. Balance of convenience. “Since the learned Single Judge, based on the materials placed before him and exercising his discretion, arrived at the finding that the balance of convenience lies in favour of the respondents/plaintiffs, stressing more on the EMR” (“Exclusive Marketing Rights”) “granted in favour of the respondents/plaintiffs under Section 24-B of the Patents Act, 1970, the validity of which has to be tested only in the trial in the suits, we find it difficult to interfere with the same.” (para 12.1)
  3. Public interest in medicines. “However, the contentions advanced on behalf of the appellants/defendants with respect to the public interest deserves serious concern as the public interest should not be made to suffer on account of legal battle between the trading parties, particularly in the case of supply of medicines for Chronic Myeloid Leukaemia.” (para 12.2)
  4. The undertaking as a condition. “In response to the concern expressed by this Court in the public interest,” counsel “fairly came forward to relax the conditions imposed in the GIPAP programme in the public interest.” (para 13.1) “Recording the undertaking of the learned Senior Counsel made on behalf of the respondents/plaintiffs, we confirm the order of interim injunction dated 28.4.2004 of the learned Single Judge” “and pending disposal of the suits,” “the respondents/plaintiffs would supply Beta-Crystalline form of Imatinib Mesylate freely to all the patients, who are suffering from Chronic Myeloid Leukaemia and are earning less than Rs. 3,36,000 per month”; “in the case of patients suffering from Chronic Myeloid Leukaemia, who are entitled for insurance for Chronic Myeloid Leukaemia, any amount which falls short of insurance policy shall be met by the respondents/ plaintiffs”; “in the case of patients suffering from Chronic Myeloid Leukaemia, who are covered under reimbursement scheme, any amount falling short of reimbursement shall be met by the respondents/plaintiffs”; and “the respondents/plaintiffs shall also file a report in compliance of the above arrangement every month before this Court in the suit as to the supply of medicines”. (paras 13.1, 14)
  5. The trial left open. “the parties are at liberty to agitate their respective contentions before the learned single Judge and the same shall be considered on merits, independently, without any reference to any of the views expressed by the learned single Judge in the order dated 28.4.2004” and “the parties are at liberty to move the learned single Judge or My Lord, the Honourable Chief Justice for expeditious disposal of the suits”. (para 14)
  6. Disposition. “all the original side appeals are disposed of accordingly. No costs. Consequently, the connected C.M. Ps are closed.” (para 14)

What the court did not decide

The Bench held that “it would not be proper for us to decide the said issue in appeals arising out of interim orders” and that the validity of the EMR (“Exclusive Marketing Rights”) “has to be tested only in the trial in the suits” (paras 11, 12.1).

Subsequent treatment

Provisions and topics

Provisions
Topics

Cases this judgment relies on

Case page

Novartis AG v Adarsh Pharma (2004)

High Court of Madras

Cited in

Case page · Page updated 19 November 2026

www.aop.onl/intas-novartis